This Biopharmaceutical Company Just Secured FDA Approval For New Drug

RedHill Biopharma's Talicia® Gains FDA Approval for 5-Year U.S. Market Exclusivity with IP Protection Through 2034.

RedHill Biopharma Ltd., a leading biopharmaceutical company, recently made headlines when the U.S. Food and Drug Administration (FDA) granted 5-year market exclusivity to its drug, Talicia®. The FDA's decision provides the Israel-based company with a significant competitive advantage in the U.S. market, securing its position in the pharmaceutical indust…